SCHEMBL11977130

SCHEMBL11977130

Cc1cn(-c2cccnc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 18/20 0.59
CDK6 Q00534 5/20 0.59
CCND3 P30281 12/20 0.58
CCND1 P24385 6/20 0.58
CCND2 P30279 6/20 0.58
FGFR1 P11362 2/20 0.56
FGFR2 P21802 2/20 0.56
FGFR4 P22455 2/20 0.56
FGFR3 P22607 2/20 0.56
NUAK1 O60285 1/20 0.56
AURKA O14965 1/20 0.56
WEE1 P30291 1/20 0.54
PLK1 P53350 1/20 0.54
CDK1 P06493 3/20 0.53
CCNB1 P14635 3/20 0.53
CCNA2 P20248 3/20 0.53
CDK2 P24941 3/20 0.53
CCNT1 O60563 2/20 0.53
CDK7 P50613 2/20 0.53
CDK9 P50750 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11977081 0.92 CDK4 (0.61) CDK4CDK6CCND3CCND1CCND2
SCHEMBL11977230 0.90 CDK4 (0.61) CDK4CDK6CCND3CCND1CCND2
SCHEMBL7713224 0.80 CDK4 (0.65) CDK4CDK6CCND3CCND1CCND2
SCHEMBL7713061 0.78 CDK4 (0.71) CDK4CDK6CCND3CCND1CCND2
SCHEMBL7710738 0.78 CDK4 (0.70) CDK4CDK6CCND3CCND1CCND2
SCHEMBL7071401 0.77 CDK4 (0.72) CDK4CDK6CCND3CCND1CCND2
SCHEMBL16570158 0.77 CDK4 (0.52) CDK4CDK6CCND3CCND1CCND2
SCHEMBL4191054 0.76 CDK6 (0.57) CDK4CDK6CCND3CCND1CCND2
SCHEMBL1976427 0.74 CDK4 (1.00) CDK4CDK6CCND1CDK1CCNB1
SCHEMBL7077958 0.74 CDK4 (1.00) CDK4CCND3CCND1CCND2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324225-B2 Pyrrolopyrimidine compounds and their uses NOVARTIS AG (CH) 2012-12-04 US disclosed
US-8324225-B2 Pyrrolopyrimidine compounds and their uses NOVARTIS AG (CH) 2012-12-04 US disclosed
US-20120207763-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
US-20120207763-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
US-20090318441-A1 Pyrrolopyrimidine Compounds and Their Uses ASTEX THERAPEUTICS LTD. 2009-12-24 US disclosed
US-20090318441-A1 Pyrrolopyrimidine Compounds and Their Uses ASTEX THERAPEUTICS LTD. 2009-12-24 US disclosed
WO-2007140222-A2 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318441-A1 Pyrrolopyrimidine Compounds and Their Uses PRKDC, TK2, PNKP CDK4 4/4885CDK6 28/4885CCND3 782/4885
US-20120207763-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES PRKDC, TK2, PNKP CDK4 4/4885CDK6 28/4885CCND3 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.